Managementul afectiunilor hematopoietice în timpul sarcinii | [Management of hematopoietic disorders during pregnancy]

Abstract

In recent decades, the incidence of malignancy has greatly increased and continues to grow among women of childbearing age. The diagnosis of onco-haematological diseases during pregnancy is made difficult. The most common disorders are lymphoma and acute leukaemia. Adverse foetal effects of chemotherapy include foetal death, birth defects, foetal neoplasia, intrauterine growth disorders and mental retardation. Maternal negative effects are those encountered in the general population. Exposure to chemotherapy in the first trimester of pregnancy increases the teratogenic risk between 10-25%. The therapies applied to pregnant women are adapting taking into account the physiological changes produced by the presence of a pregnancy. Most therapeutic schemes need abortion if the treatment is initiated in the first trimester of pregnancy. In the 2nd or 3rd trimesters of pregnancy, antineoplastic therapy is initiated using less aggressive therapeutic options.